论文部分内容阅读
目的探索黛立新联合兰索拉唑、伊托必利治疗难治性胃食管反流病的临床疗效。方法将89例难治性胃食管反流病患者随机分为A(治疗)组45例,B(对照)组44例。分别采用黛立新+兰索拉唑+伊托必利、兰索拉唑+伊托必利+铝碳酸镁治疗。2、4周评价临床症状改善情况。结果治疗2周后,A、B组患者临床症状改善率分别为86.6%和72.7%,P>0.05,无统计学差异;治疗4周后A、B患者临床症状改善率为95.5%和79.5%,P<0.05,差异显著。结论黛立新联合兰索拉唑、伊托必利治疗难治性胃食管反流病4周能达到理想的临床疗效。
Objective To explore the clinical efficacy of Dai Lixin combined with lansoprazole and itopride in the treatment of refractory gastroesophageal reflux disease. Methods 89 patients with refractory gastroesophageal reflux disease were randomly divided into A (treatment group) 45 cases, B (control group) 44 cases. Respectively use Dai Lixin + Lansoprazole + Itopride, Lansoprazole + Itopride + magnesium aluminum carbonate treatment. 2,4 week evaluation of clinical symptoms improved. Results After 2 weeks of treatment, the clinical symptom improvement rates in group A and group B were 86.6% and 72.7%, respectively, with no significant difference (P> 0.05). After 4 weeks of treatment, the clinical symptom improvement rates in group A and B were 95.5% and 79.5% , P <0.05, significant difference. Conclusions Dai Lixin combined with lansoprazole and Itopride can achieve the desired clinical effect in the treatment of refractory gastroesophageal reflux disease for 4 weeks.